Using CellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3841-3852

  Reinhold, William C ^a   Sunshine, Margot ^a,b   Varma, Sudhir ^a,b,c   Doroshow, James H ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENERAL DYNAMICS   (United States)

^c HiThru Analytics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DNA; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RNA; RO 5126766; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACCESS TO INFORMATION; CANCER CELL LINE; DATA ANALYSIS SOFTWARE; DATA BASE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC VARIABILITY; GENOME ANALYSIS; INFORMATION RETRIEVAL; ONCOGENE RAS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEQUENCE ANALYSIS; SYSTEM ANALYSIS; WHOLE EXOME SEQUENCING; BIOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; EXOME; FACTUAL DATABASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; PROCEDURES; SOFTWARE; TUMOR CELL LINE; WEB BROWSER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DISCOVERY; EXOME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SOFTWARE; WEB BROWSER;

EID: 84942849725     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0335     Document Type: Review

References (46)

1. Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 2009; 10: 277.
2. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a Web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012; 72: 3499-511.
3. CellMiner [database on the Internet]. Bethesda, MD: National Cancer Institute [cited 2015 Apr 13]. Available from: http://discover.nci.nih.gov/cellminer/.
4. Genomics and Bioinformatics Group [homepage on the Internet]. Bethesda, MD: National Cancer Institute [cited 2015 Apr 13]. Available from: http://discover.nci.nih.gov/.
5. Developmental Therapeutics Program [homepage on the Internet]. Bethesda, MD: National Cancer Institute [cited 2015 Apr 13]. Available from: https://dtp.nci.nih.gov/.
6. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82: 1113-8.
7. Lorenzi P, Reinhold W, Varma S, Hutchinson A, Pommier Y, Chanock S, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009; 8: 713-24.
8. Varma S, Pommier Y, Sunshine M, Weinstein JN, Reinhold WC. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS One 2014; 9: e92047.
9. Reinhold W, Reimers M, Maunakea A, Kim S, Lababidi S, Scherf U, et al. Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther 2007; 6: 391-403.
10. Abaan OD, Poley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 2013; 73: 4372-82.
11. Ikediobi O, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of twenty-four known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006; 5: 2606-12.
12. Szakacs G, Annereau J, Lababidi S, Shankavaram U, Arciello A, Bussey K, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129-37.
13. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther 2010; 9: 1080-91.
14. Reinhold WC, Varma S, Sousa F, Sunshine M, Abaan OD, Davis SR, et al. NCI-60 Whole exome sequencing and pharmacological CellMiner analyses. PLoS One 2014; 9: e101670.
15. Nishizuka S, Charboneau L, Young L, Major S, Reinhold W, Waltham M, et al. Proteomic profiling of the NCI60 cancer cell lines using new high-density 'reverse-phase' lysate microarrays. Proc Natl Acad Sci U S A 2003; 100: 14229-34.
16. AbMiner [database on the Internet]. Bethesda, MD: National Cancer Institute [cited 2015 Apr 13]. Available from: http://discover.nci.nih.gov/abminer/.
17. Major SM, Nishizuka S, Morita D, Rowland R, Sunshine M, Shankavaram U, et al. AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinformatics 2006; 7: 192.
18. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 2012; 109: 15030-5.
19. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-5.
20. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 2010; 9: 3105-14.
21. 1000 Genomes [homepage on the Internet]. Cambridgeshire, UK: The European Bioinformatics Institute; 2008-11 [cited 2015 Apr 15]. Available from: http://www.1000genomes.org/.
22. NHLBI Exome Sequencing Project (ESP) [database on the Internet]. Seattle, WA: University of Washington; 2011 [cited 2015 Apr 15]. Available from: http://evs.gs.washington.edu/EVS/.
23. Ruffini F, Tentori L, Dorio AS, Arcelli D, D'Amati G, D'Atri S, et al. Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. Oncology Rep 2013; 30: 2887-96.
24. Filimon A, Zurac SA, Milac AL, Sima LE, Petrescu SM, Negroiu G. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors. Melanoma Res 2014; 24: 219-36.
25. Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 2014; 60: 83-8.
26. Funt SA, Page DB, Wolchok JD, Postow MA. CTLA-4 antibodies: new directions, new combinations. Oncology (Williston Park) 2014; 28 Suppl 3: 6-14.
27. Forloni M, Dogra SK, Dong Y, Conte D Jr, Ou J, Zhu LJ, et al. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. eLife 2014; 3: e01460.
28. Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude LG, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 2011; 24: 525-37.
29. Patrawala S, Puzanov I. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncol 2012; 8: 509-23.
30. Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013; 14: 733-40.
31. Uluer ET, Aydemir I, Inan S, Ozbilgin K, Vatansever HS. Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta Histochem 2012; 114: 641-6.
32. Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol 2009; 5: 105-16.
33. Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol 2015; 141: 671-89.
34. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
35. Rodriguez-Escudero I, Oliver MD, Andres-Pons A, Molina M, Cid VJ, Pulido R. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum Mol Genet 2011; 20: 4132-42.
36. Janardhanan R, Banik NL, Ray SK. N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Biochem Pharmacol 2009; 78: 1105-14.
37. Eddy J, Vallur AC, Varma S, Liu H, Reinhold WC, Pommier Y, et al. G4 motifs correlate with promoter-proximal transcriptional pausing in human genes. Nucleic Acids Res 2011; 39: 4975-83.
38. Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, et al. Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res 2010; 70: 2191-203.
39. Jung H, Wang H, Patel R, Phillips B, Reinhold W, Cohen D, et al. miR-375 regulation of CIP2A controls oral cancer cell proliferation and survival. Mol Biol Cell 2013; 24: 1638-48.
40. Zoppoli G, Douarre C, Dalla Rosa I, Liu H, Reinhold W, Pommier Y. Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Res 2011; 39: 6620-32.
41. Giovinazzi S, Morozov VM, Summers MK, Reinhold WC, Ishov AM. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase. Cell Death Differ 2013; 20: 721-31.
42. Kohn KW, Zeeberg BR, Reinhold WC, Sunshine M, Luna A, Pommier Y. Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes. PLoS One 2012; 7: e35716.
43. Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V. Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS One 2011; 6: e25991.
44. Ruan X, Kocher JP, Pommier Y, Liu H, Reinhold WC. Mass homozygotes accumulationinthe NCI-60 cancer cell linesascomparedtoHapMap trios, and relation to fragile site location. PLoS One 2012; 7: e31628.
45. Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFbeta interaction. Proc Natl Acad Sci U S A 2012; 109: 14592-7.
46. Kohn KW, Zeeberg BM, Reinhold WC, Pommier Y. Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. PLoS One 2014; 9: e99269.